Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its second quarter 2020 revenues were up 23 percent year over year.

The liquid biopsy and cancer early detection firm reported total revenues of $66.3 million for the quarter ended June 30 compared to $54.0 million in the same period of 2019, beating the $59.2 million that Wall Street had predicted on average.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.